17th Sep 2025 03:34
(Alliance News) - GSK PLC on Wednesday announced plans to spend a minimum of USD30 billion over the coming five years to improve its US manufacturing facilities and research and development capabilities.
GSK is a pharmaceutical and biotechnology company based in London and is a constituent of the UK's FTSE 100 blue-chip stock index.
The company said the USD30 billion investment includes a commitment to spend USD1.2 billion in advanced manufacturing facilities, artificial intelligence, and advanced digital technologies, to deliver next-generation biopharma factories and laboratories in the US.
"These investments build on GSK’s strong innovation and manufacturing footprint and capabilities in the United States today, developing and making products in the United States for the United States," GSK commented.
The USD1.2 billion will be partly allocated towards the construction of a new biologics flex factory in Upper Merion, Pennsylvania, with construction scheduled to begin in 2026.
It will also contribute to developing new AI and digital technology capabilities at five existing manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana.
In particular, the investment will focus on new drug substance manufacturing capabilities and enhanced device and auto-injector capabilities and assembly.
Chief Executive Officer Emma Walmsley said: "Here in the UK, we continue to invest in a significant manufacturing base and more than GBP1.5 billion in R&D every year. Today, we are committing to invest at least GBP30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country."
With this latest announcement, GSK has committed new investments in the US of approximately USD2 billion over the last twelve months.
In 2024, the company spent a total of GBP6.4 billion, approximately USD8.73 billion, on R&D investments across its portfolio, representing a 3% increase on an actual exchange rate basis from the prior year, or 5% at constant exchange rates.
GSK shares closed down 0.9% at 1,465.69 pence in London on Tuesday, while shares listed in New York closed 0.6% lower at USD40.05.
By Elijah Dale, Alliance News senior reporter Asia-Pacific
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline